What does collaboration revenue (ZURZUVAE) — total revenues mean?

This metric represents the total revenue recognized from collaborative arrangements or licensing agreements associated with a specific pharmaceutical product or therapeutic candidate. It reflects the financial inflows generated through partnerships, milestone payments, or profit-sharing models rather than direct product sales. Monitoring this revenue stream provides insight into the company's ability to monetize its research and development pipeline through strategic external alliances.

Supernus Pharmaceuticals SUPN Collaboration revenue (ZURZUVAE) — Total revenues

Other product segments

Qelbree

$77.84M+20.2%

GOCOVRI

$35.24M+14.8%

Royalty, licensing, and other revenues

$29.31M+274%

Trokendi XR

$9.48M-26.0%

ONAPGO

$8.38M—

APOKYN

$7.73M-48.4%

Oxtellar XR

$7.42M-27.2%

Other

$4.67M-45.6%

Similar metrics at other companies

BIIBZURZUVAE — Total Revenue

$55.4M+100%

NRIXCollaboration revenue — Revenue

$6.25M-66.1%

CRNXCollaboration and license revenue — Total Revenue

$428K+18.6%

NBIXCollaboration revenues — Total revenues

$3.5M-60.7%

VRDNCollaboration — Total revenues

$135K+35.0%

ALMSCollaboration Revenue — Revenue

$1.74M—

Other financials

Income statement

See full

Revenue$207.7M+38.6%

Gross profit$184.3M+37.5%

Operating income-$8.3M+18.8%

Net income-$2.3M+80.6%

EPS (diluted)-$0.04+81.0%

Balance sheet

See full

Cash & equivalents$186.3M+60.8%

Total debt$40.9M+26.6%

Total equity$1.1B+4.5%

Total assets$1.5B+11.4%

Cash flow

See full

Operating cash flow$66.5M+117%

CapEx--100%

Free cash flow$66.5M+120%

Valuation

See full

Market cap$2.58B+62.8%

Enterprise value$2.44B+62.3%

P/S3.3×+0.9×

Profitability

See full

Gross margin89.4%+1.0pp

Operating margin-7.8%-18.9pp

Net margin-3.7%-13.0pp

FCF margin27.9%+3.4pp

Returns & leverage

See full

Return on equity-2.8%-9.1pp

Debt / equity0×0.0×

Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's collaboration revenue (zurzuvae) — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Supernus Pharmaceuticals's collaboration revenue (ZURZUVAE) — total revenues?: Supernus Pharmaceuticals (SUPN) reported collaboration revenue (ZURZUVAE) — total revenues of $27.64M in Q1 2026.
What does collaboration revenue (ZURZUVAE) — total revenues mean?: This metric represents the total revenue recognized from collaborative arrangements or licensing agreements associated with a specific pharmaceutical product or therapeutic candidate. It reflects the financial inflows generated through partnerships, milestone payments, or profit-sharing models rather than direct product sales. Monitoring this revenue stream provides insight into the company's ability to monetize its research and development pipeline through strategic external alliances.